Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer to launch OTC antihistamine/vasoconstrictor product in coming months.

This article was originally published in The Tan Sheet

Executive Summary

PFIZER ADDING OTC ANTIHISTAMINE/VASOCONSTRICTOR PRODUCT to its consumer eyecare offering. The product, which will be marketed by Pfizer's Consumer Health Care Group under a 1994 licensing agreement with Akorn, Inc., is expected to be launched in the coming months. FDA approved Akorn's Rx-to-OTC switch NDA for the pheniramine maleate .3%/naphazoline HCl 0.25% eye drops under the name OcuHist on Jan. 31.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel